Yanan Gao1, Qiong Lyu2, Peng Luo2, Mujiao Li3, Rui Zhou3, Jian Zhang2, Qingwen Lyu4. 1. Department of Radiotherapy, Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, People's Republic of China. 2. Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China. 3. School of Biomedical Engineering, Southern Medical University, Guangzhou, People's Republic of China. 4. Department of Information, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Abstract
PURPOSE: Lung cancer, mainly lung adenocarcinoma, lung squamous cell carcinoma and small cell lung cancer, has the highest incidence and cancer-related mortality worldwide. Platinum-based chemotherapy plays an important role in the treatment of various lung cancer subtypes, but not all patients benefit from this treatment regimen; thus, it is worth identifying lung cancer patients who are resistant or sensitive to platinum-based therapy. METHODS: The drug response and sequencing data of 170 lung cancer cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database, and support vector machines (SVMs) and beam search were used to select an optimal gene panel that can predict the sensitivity of cell lines to cisplatin. Then, we used available cell line data to explore the potential mechanisms. RESULTS: In this work, the drug response and sequencing data of 170 lung cancer cell lines were downloaded from the GDSC database, and SVMs and beam search were used to screen a panel of genes related to lung cancer cell line resistance to cisplatin. A final panel of nine genes (PLXNC1, KIAA0649, SPTBN4, SLC14A2, F13A1, COL5A1, SCN2A, PLEC, and ALMS1) was identified, and achieved an area under the curve (AUC) of 0.873 ± 0.004. The natural logarithm of the half maximal inhibitory concentration (lnIC50) values of the mutant-type (panel-MT) group was significantly higher than that of the wild-type (panel-WT) group, regardless of the lung cancer subtype. The differentially expressed pathways between the two groups may explain this difference. CONCLUSION: In this study, we found that a panel of nine genes can accurately predict sensitivity to cisplatin, which may provide individualized treatment recommendations to improve the prognosis of patients with lung cancer.
PURPOSE: Lung cancer, mainly lung adenocarcinoma, lung squamous cell carcinoma and small cell lung cancer, has the highest incidence and cancer-related mortality worldwide. Platinum-based chemotherapy plays an important role in the treatment of various lung cancer subtypes, but not all patients benefit from this treatment regimen; thus, it is worth identifying lung cancer patients who are resistant or sensitive to platinum-based therapy. METHODS: The drug response and sequencing data of 170 lung cancer cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) database, and support vector machines (SVMs) and beam search were used to select an optimal gene panel that can predict the sensitivity of cell lines to cisplatin. Then, we used available cell line data to explore the potential mechanisms. RESULTS: In this work, the drug response and sequencing data of 170 lung cancer cell lines were downloaded from the GDSC database, and SVMs and beam search were used to screen a panel of genes related to lung cancer cell line resistance to cisplatin. A final panel of nine genes (PLXNC1, KIAA0649, SPTBN4, SLC14A2, F13A1, COL5A1, SCN2A, PLEC, and ALMS1) was identified, and achieved an area under the curve (AUC) of 0.873 ± 0.004. The natural logarithm of the half maximal inhibitory concentration (lnIC50) values of the mutant-type (panel-MT) group was significantly higher than that of the wild-type (panel-WT) group, regardless of the lung cancer subtype. The differentially expressed pathways between the two groups may explain this difference. CONCLUSION: In this study, we found that a panel of nine genes can accurately predict sensitivity to cisplatin, which may provide individualized treatment recommendations to improve the prognosis of patients with lung cancer.
Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701
Authors: Chavalit Supsrisunjai; Chao-Kai Hsu; Magdalene Michael; Cédric Duval; John Y W Lee; Hsing-San Yang; Hsin-Yu Huang; Thitiwat Chaikul; Alexandros Onoufriadis; Roberto A Steiner; Robert A S Ariëns; Ofer Sarig; Eli Sprecher; Marina Eskin-Schwartz; Curt Samlaska; Michael A Simpson; Eduardo Calonje; Maddy Parsons; John A McGrath Journal: J Invest Dermatol Date: 2019-09-04 Impact factor: 8.551
Authors: Francesco Iorio; Theo A Knijnenburg; Daniel J Vis; Graham R Bignell; Michael P Menden; Michael Schubert; Nanne Aben; Emanuel Gonçalves; Syd Barthorpe; Howard Lightfoot; Thomas Cokelaer; Patricia Greninger; Ewald van Dyk; Han Chang; Heshani de Silva; Holger Heyn; Xianming Deng; Regina K Egan; Qingsong Liu; Tatiana Mironenko; Xeni Mitropoulos; Laura Richardson; Jinhua Wang; Tinghu Zhang; Sebastian Moran; Sergi Sayols; Maryam Soleimani; David Tamborero; Nuria Lopez-Bigas; Petra Ross-Macdonald; Manel Esteller; Nathanael S Gray; Daniel A Haber; Michael R Stratton; Cyril H Benes; Lodewyk F A Wessels; Julio Saez-Rodriguez; Ultan McDermott; Mathew J Garnett Journal: Cell Date: 2016-07-07 Impact factor: 41.582
Authors: Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton Journal: Genome Med Date: 2017-04-19 Impact factor: 11.117
Authors: Matt R Paul; Tien-Chi Pan; Dhruv K Pant; Natalie Nc Shih; Yan Chen; Kyra L Harvey; Aaron Solomon; David Lieberman; Jennifer Jd Morrissette; Danielle Soucier-Ernst; Noah G Goodman; S William Stavropoulos; Kara N Maxwell; Candace Clark; George K Belka; Michael Feldman; Angela DeMichele; Lewis A Chodosh Journal: J Clin Invest Date: 2020-08-03 Impact factor: 19.456